PubMed
Growth hormone-releasing peptide-6 stimulates GH, ACTH, and cortisol release
Arvat E, Maccario M, Di Vito L, et al. J Clin Endocrinol Metab. 1998
Compare
GHRP-6 vs LL-37
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
GHRP-6
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 83% · Mixed 17% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
1
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 100–400 mcg
100–200
2
200–400
4
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
LL-37
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 100–400 mcg
100–200
4
200–400
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Sources (7)
Published sources linked on the GHRP-6 and LL-37 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
- Wiki study page →Source
PubMed
LL-37, the only human member of the cathelicidin family of antimicrobial peptides
Vandamme D, Landuyt B, Luyten W, et al. Biochim Biophys Acta. 2012
- Wiki study page →Source
PubMed
The antimicrobial peptide LL-37 inhibits biofilm formation
Dean SN, Bishop BM, van Hoek ML. BMC Microbiol. 2011
- Wiki study page →Source
ClinicalTrials.gov
LL-37 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Rosacea: Pathogenesis and Therapeutic Correlates
Geng RSQ, Bourkas AN, Mufti A, et al. Journal of cutaneous medicine and surgery. 2024
- Wiki study page →Source
PubMed
LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review
Soman D, P J, Cm M, et al. Archives of oral biology. 2026